Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Doug_Drysdale
|
| gptkbp:collaboratesWith |
academic institutions
|
| gptkbp:country |
gptkb:Canada
|
| gptkbp:developedBy |
DMT-based therapeutics
novel psychedelic compounds psilocybin-based therapeutics |
| gptkbp:focusesOn |
mental health treatments
psychedelic therapeutics |
| gptkbp:foundedYear |
2019
|
| gptkbp:hasPatentApplications |
novel psychedelic compounds
psychedelic delivery systems |
| gptkbp:headquartersLocation |
gptkb:Toronto,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cybin Inc.
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:listedOn |
gptkb:Toronto_Stock_Exchange
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:researchInterest |
gptkb:depression
addiction anxiety psychiatric disorders |
| gptkbp:stockExchange |
gptkb:NYSE_American
gptkb:NEO_Exchange |
| gptkbp:stockSymbol |
gptkb:CYBN
|
| gptkbp:subsidiary |
Adelia Therapeutics Inc.
|
| gptkbp:website |
https://www.cybin.com/
|
| gptkbp:bfsParent |
gptkb:CYBN
|
| gptkbp:bfsLayer |
7
|